Teva (TEVA) Appoints Rob Koremans as CEO of Teva Europe
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $37.55 +3.76%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -5.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -5.6%
Join SI Premium – FREE
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) reports that Dr. Rob Koremans, has been appointed President and CEO, Teva Europe and will join the company in March 2012. Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis.
After six intensive years, Dr. Gerard van Odijk, Teva Europe’s current President and CEO has decided to step down.
In the next few months, Dr. Koremans and Dr. van Odijk will work closely together to ensure a smooth transition. Dr. van Odijk will remain with Teva to support the EU region for the remainder of 2012.
After six intensive years, Dr. Gerard van Odijk, Teva Europe’s current President and CEO has decided to step down.
In the next few months, Dr. Koremans and Dr. van Odijk will work closely together to ensure a smooth transition. Dr. van Odijk will remain with Teva to support the EU region for the remainder of 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva in talks with Trump administration on Medicaid drug pricing
- Calix names Juergen Lindner as chief marketing officer
- Sparton, Glen Eagle ink joint venture deal for Ontario silver mine
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
